Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

Recent & Breaking News (NDAQ:JAZZ)

Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

PR Newswire Europe Non Regulatory July 19, 2018

Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt

PR Newswire June 29, 2018

Vyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

PR Newswire June 29, 2018

Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

PR Newswire Europe Non Regulatory June 27, 2018

Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference

PR Newswire Europe Non Regulatory June 6, 2018

Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open Text, and ChemoCentryx — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire June 4, 2018

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

PR Newswire Europe Non Regulatory June 3, 2018

Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

PR Newswire Europe Non Regulatory June 3, 2018

New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea

PR Newswire Europe Non Regulatory May 31, 2018

Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

PR Newswire Europe Non Regulatory May 24, 2018

Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting

PR Newswire Europe Non Regulatory May 10, 2018

Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

PR Newswire Europe Non Regulatory May 9, 2018

Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results

PR Newswire Europe Non Regulatory May 8, 2018

Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Benzinga.com  May 8, 2018

Earnings Scheduled For May 8, 2018

Benzinga.com  May 8, 2018

Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

PR Newswire Europe Non Regulatory May 1, 2018

Merger Monday Makes A Return

Benzinga.com  April 30, 2018

Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018

PR Newswire Europe Non Regulatory April 24, 2018

Research Report Identifies Yirendai, Atlantic Capital Bancshares, Jazz Pharmaceuticals, Sina, Akebia Therapeutics, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire April 9, 2018

Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

PR Newswire March 6, 2018